相关临床试验
159
30 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1999
进行中（未招募）
17
10.7%
已完成
85
53.5%
尚未招募
13
8.2%
招募中
32
20.1%
终止
5
3.1%
Unknown
2
1.3%
撤回
5
3.1%
暂无批准数据
- The RADICAL PC-2 trial enrolled 2,501 prostate cancer patients across eight countries and found routine referral to a cardiologist or internist significantly improved cholesterol control and statin use. - Referred patients were more likely to receive statin therapy (63% vs. 40%) and blood pressure medication (56% vs. 49%), with significantly lower cholesterol levels over nearly six years of follow-up. - Despite these improvements, no significant difference emerged in cardiovascular death, heart attack, stroke, or heart failure between the referred and usual-care groups. - A prespecified subgroup analysis identified patients with cholesterol above 4 mmol/L, blood pressure above 130/80, or diabetes as most likely to benefit from specialist referral.
- Bayer announced positive topline results from the Phase III OCEANIC-STROKE study, with asundexian significantly reducing ischemic stroke risk compared to placebo in over 12,300 patients. - The once-daily oral Factor XIa inhibitor demonstrated no increased risk of major bleeding when combined with antiplatelet therapy in secondary stroke prevention. - The study addresses a critical unmet need, as one in five stroke survivors experiences another stroke within five years despite current prevention options. - Asundexian has received FDA Fast Track Designation for stroke prevention in patients after non-cardioembolic ischemic stroke, with detailed results to be presented at an upcoming scientific congress.
- AMO Pharma has initiated the TaRGET Phase 2 trial, the largest clinical study ever conducted for arrhythmogenic right ventricular cardiomyopathy (ARVC), enrolling 120 patients across 17 Canadian sites. - The investigational therapy AMO-02 targets glycogen synthase kinase-3 beta (GSK3β), addressing the underlying disease biology of ARVC caused by genetic mutations in desmosomal genes. - Preclinical studies demonstrated that AMO-02 reduced arrhythmias and cardiomyopathy while preventing disease progression and reversing existing features in mouse models with human ARVC mutations. - The randomized, double-blind, placebo-controlled trial will measure changes in premature ventricular contractions over six months, with first results expected in Q2 2027.
- AtriCure has completed enrollment of 6,500 patients across 137 global centers in the LeAAPS clinical trial, marking the largest cardiac surgery device trial ever conducted. - The prospective, randomized, blinded superiority trial evaluates the AtriClip LAA Exclusion System for preventing ischemic stroke in cardiac surgery patients without prior atrial fibrillation history. - The trial targets a large underserved population of over one million annual cardiac surgery patients, with more than 70% having no preoperative atrial fibrillation diagnosis. - Results are expected to inform clinical practice guidelines and support expanded stroke prevention indications for AtriClip devices, with five years of follow-up planned.
- The ACHIEVE trial, the largest study to date with 2,538 dialysis patients across 12 countries, found that spironolactone did not significantly reduce cardiovascular death or heart failure hospitalization compared to placebo. - Cardiovascular events occurred in 20.5% of spironolactone patients versus 21.6% of placebo patients, with no statistically significant difference between groups. - Spironolactone increased the risk of severe hyperkalemia by 44%, occurring in 6.6% of treated patients compared to 4.5% receiving placebo. - The trial was stopped early for futility after an independent monitoring committee determined there was little chance of seeing meaningful cardiovascular benefit.
